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Abstract: Recent studies on Andean children indicate a prevalence of dyslipidemia and hypertension
compared to dwellers at lower altitudes, suggesting that despite similar food intake and daily
activities, they undergo different metabolic adaptations. In the present study, the sphingolipid
pattern was investigated in serum of 7 underweight (UW), 30 normal weight (NW), 13 overweight
(OW), and 9 obese (O) Andean children by liquid chromatography-mass spectrometry (LC-MS).
Results indicate that levels of Ceramides (Cers) and sphingomyelins (SMs) correlate positively
with biochemical parameters (except for Cers and Vitamin D, which correlate negatively), whereas
sphingosine-1-phosphate (S1P) correlates negatively. Correlation results and LC-MS data identify the
axis high density lipoprotein-cholesterol (HDL-C), Cers, and S1P as related to hypoxia adaptation.
Specifically UW children are characterized by increased levels of S1P compared to O and lower
levels of Cers compared to NW children. Furthermore, O children show lower levels of S1P and
similar levels of Cers and SMs as NW. In conclusion, our results indicate that S1P is the primary
target of hypoxia adaptation in Andean children, and its levels are associated with hypoxia tolerance.
Furthermore, S1P can act as marker of increased risk of metabolic syndrome and cardiac dysfunction
in young Andeans living at altitude.
Keywords: high-altitude hypoxia; dyslipidemia; sphingolipids; ceramides; sphingosine-1-phosphate;
sphingomyelins; LC-MS/MS
1. Introduction
Several studies have addressed the comprehension of molecular mechanisms at the basis of a
high-altitude hypoxia adaptation of Andeans and Tibetans, allowing them to permanently inhabit
at 3500–4500 m of altitude [1–3]. These two ethnic groups are characterized by different traits
associated with adaptive responses to hypobaric hypoxia, however the molecular mechanisms are
still not completely clear. Advanced genome-wide scanning identified genes and genetic variants that
contribute to human adaptation to altitude in Tibetans [4,5] and Andeans [6,7], confirming different
adaptive mechanisms. Specifically, Andeans appear to develop metabolic syndrome [8], which is
not described in Tibetans, and they have elevated hemoglobin concentrations compared to Tibetans,
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suggesting a different trait in oxygen delivery and metabolism [9–12]. Hypoxia is a key factor involving
most of the major biological pathways that contribute to respiratory dysfunctions, cardiovascular
disorders and diabetes, and genetic studies of high altitude dwellers have focused on key genes of
the hypoxia inducible factor (HIF) pathway that detect and react to oxygen shortage. Mutations and
polymorphisms were identified in Endothelial PAS Domain Protein 1 (EPAS1) and Egl-9 Family Hypoxia
Inducible Factor 1 (EGLN1), providing a gene signature of these populations [13,14]. Furthermore, a
positive selection for nitric oxide synthase 2 (NOS2A) has been described [6] in Andeans, even though
this pattern cannot fully explain discrepancies in body weight composition and dyslipidemia observed
in this population [15,16].
Recent studies on Koya children (a community born and living in the Andean region of Salta
Province, 3750 m a.s.l.) indicate a higher prevalence of dyslipidemia and hypertension compared
to a similar background community living at lower altitudes in Chicoana (CH), 1400 m a.s.l. [16,17],
suggesting that despite similar food intake and daily activities, Koya children undergo a different
metabolic adaptation. Furthermore, a study performed in San Antonio de los Cobres (SAC; a city
located at 3775 m a.s.l.) on school children showed a higher prevalence of dyslipidemia compared to
urban Buenos Aires children (BA) living at sea level [8]. It must be pointed out that SAC children had
higher triglyceride and lower HDL-C concentrations than BA children, with both groups belonging
to a similar ethnicity, suggesting that exposure to altitude might be the main factor associated with
dyslipidemia. Moreover, high atherogenic risk is also indicated by different lipid-related indexes, such
as total cholesterol/HDL-C, triglycerides/HDL-C, and low density lipoprotein-cholesterol (LDL-C)
LDL-C/HDL-C. Furthermore, higher levels of triglycerides/HDL-C index were associated with an
increased proportion of small and dense LDL-C [18–20].
The aim of the present study is to unravel the contribution of sphingolipids in metabolic adaptation
among Koya children born and living at altitude (3775 m a.s.l.), in order to have better insights into
the metabolic characteristics of this group with different body weight composition, and to identify
markers that are able to predict the development of cardiovascular disease and diabetes in adulthood.
It is known that the total cellular ceramide (Cers) concentration increases in cell models in response
to various stresses, such as hypoxia and restricted blood supply (ischemia), and that sphingosine 1
phosphate (S1P) is an important signaling molecule derived from ceramide degradation [21,22].
Cers are synthesized through three different pathways: the de novo biosynthesis pathway from
palmitoyl-CoA and serine; the sphingomyelin hydrolysis pathway (SMase pathway), which generates
Cers from SMs; and the salvage pathway, which generates ceramides from the catabolism of complex
glycosphingolipids. Biochemically, individual ceramide synthases (CerS) isoforms (from 1 to 6)
show substrate preference for specific chain length fatty acyl-CoAs, thus generating ceramides with
different acyl-chains, which have been associated with obesity and glucose intolerance [23]. Ceramide
is converted to sphingosine by ceramidase, and then sphingosine is phosphorylated into S1P by
sphingosine kinase (SphK) 1 or 2, located in the cytosol and in the nucleus, respectively [24–26]. S1P is
quickly degraded by specific phosphatases and lyases localized in the endoplasmic reticulum (ER) [27].
The relationship between ceramides and a high-fat diet was demonstrated in mice, in which
alterations of muscle ceramide levels and glucose tolerance were associated with a high-fat diet [28].
These alterations were ameliorated by treatment with myriocin, an inhibitor of de novo biosynthesis,
highlighting the central role of ceramide in metabolic changes. Ceramide increment alters mitochondria
membrane permeability, inhibits electron transport chain intermediates, and promotes mitochondria
oxidative stress [29]. Furthermore, ceramides levels can be cause [30] and effector [31], leading to
peripheral and central insulin resistance that contribute to diabetes [32].
To characterize the contribution of sphingolipids associated with hypoxia in obesity, we investigate
their differential abundance of sphingolipids in serum of UW, NW, OW, and O Koya children by
combining a single phase extraction method with high resolution LC-MS analyses and multiple reaction
monitoring (MRM).
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2. Results
2.1. Biochemical Parameters Assessment
Biochemical assessment is summarized in Table 1. UW and OW groups were characterized by
mean levels of TC defined as acceptable by the National Cholesterol Educational Program [33], while
NW and O subjects showed borderline levels for total cholesterol (TC). Acceptable levels of mean
HDL-C were detected only in NW subjects, while other groups showed lower mean levels of HDL-C,
classifying them as borderline [33]. LDL-C mean levels were acceptable for all groups, being lower
than 110 mg/dL, whereas all groups showed borderline levels of mean triglycerides (TG), except O
subjects, which showed high levels [34]. Mean levels of Vitamin D were assessed and all groups were
deficient [35,36]. Mean glycaemia was beneath alert limits for all groups [34].
Table 1. Study participant’s anthropometry and biochemical assessment. Characteristics are described
using median and interquartile range (if continuous) or counts and percentages (if categorical). One
way ANOVA with Bonferroni’s correction was employed if data were normally distributed, otherwise
Kruskal-Wallis’ with Dunn’s correction was adopted. (* represent p-value for UW, + represent p-value
for NW, y represent p-value for O) * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, + p-value < 0.05,
++ p-value< 0.01, +++ p-value< 0.001, yy p-value < 0.01.
Anthropometric
and Biochemical
Parameters
UW NW OW O
N. 7 (43.7 %) 30 (44.1 %) 13 (65 %) 9 (50%)
Age 11 (8.5/11) 9 (8/11) 11 (10/11) 9 (8/9)
Weight (Kg) 25.2 (21.8/27.1) 27.2 (22.6/32.6) 45 (37.3/49.5) ***,+++ 38.6 (37.6/42) **,++
Height (Cm) 134 (124/138.5) 129.5 (121.7/140.7) 145 (134/149) 130 (124/137)
BMI 14 (13.7/14.3) 15.765 (14.9/16.9) 20.9 (18.6/22) ***,++ 23.9 (22.5/25.6) ***,+++
Gender (M) 4 (57,1 %) 15 (50 %) 7 (53,8 %) 4 (44,4 %)
TC (mg/dL) 148 (128.5/163) 170 (166/180.5) 159 (140/170) 174 (148/193)
HDL-C (mg/dL) 43 (41/53) 50.5 (45/59.5) yy 45 (40/50) 42 (32/46)
TC/HDL-C 3.1 (2.8/3.3) 3.35 (2.9/3.7) 3.7 (3.2/3.9) 4.1 (3.7/4.8) *,++
LDL-C (mg/dL) 81 (74/90.5) 99.5 (94.2/104.7) 85 (81/100) 101 (89/104)
Vit. D (ng/mL) 14.2 (14/16.1) 17.2 (14.6/21.2) 16.2 (12.7/18.8) 15.8 (14.3/18.3)
Glycaemia (mg/dL) 88 (82/92) 83.5 (79.5/87.7) 85 (81/88) 84 (81/88)
HOMA-IR 1 (0.9/1.2) 0.9 (0.6/1.1) 1.7 (1.1/1.7) + 1.5 (1.3/2) ++
Insulin (µU/mL) 5.1 (3.9/5.6) 4.4 (3/5.6) 7.7 (5.5/8.7) + 7.2 (6.4/9.3) ++
TG (mg/dL) 83 (72.5/95.5) 97 (78.2/113.7) 90 (86/122) 129 (97/143)
2.2. Anthropometrics and Biochemical Differences
Data from comparison of biochemical parameters and anthropometric characteristics are
summarized in Table 1.
HDL-C was higher in NW subjects compared to O (p-value < 0.01), whereas TC/HDL-C ratio was
higher in O subjects compared to UW and NW (p-value < 0.05 and 0.01, respectively). Homeostatic
Model assessment for insulin resistance (HOMA-IR) and insulin were higher in obese and overweight
subjects compared to NW (p-value < 0.01 and 0.05, respectively, in both comparisons).
2.3. Sphingolipids and Biochemical Parameters Correlation
Scatter plots of total Cers, total SMs, and S1P levels with main biochemical parameters are
summarized in Figure 1; a correlation table can be found in Supplementary Table S1.
UW subjects showed a positive correlation between SMs levels and HDL-C (r = 0.854,
p-value = 0.015).
In NW subjects, Cers showed a positive correlation with HOMA-IR (r = 0.389, p-value= 0.0336),
insulin (r = 0.418, p-value = 0.021), and TG (r = 0.379, p-value= 0.039), and a negative correlation with
Vitamin D (r = −0.4, p-value = 0.028). In the same group of subjects, a negative correlation (r = −0.375,
p-value = 0.041) was also identified between S1P and HDL-C, while no correlations were found for SMs.
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In OW subjects, total Cers show a positive correlation with TC (r = 0.721, p-value = 0.005),
LDL-C (r = 0.691, p-value = 0.024), as well as total SMs that strongly correlate with TC (r = 0.726,
p-value = 0.005), LDL-C (r = 0.655, p-value = 0.015), and HDL-C (r = 0.603, p-value = 0.029), whereas
S1P was negatively correlated with LDL-C levels (r = −0.691, p-value = 0.011).
In O subjects, a correlation was found comparing Cers and Glycaemia (r = 0.683, p-value = 0.043).
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Figure 1. Total Ceramide (A), total sphingomyelin (B), and total S1P (C) scatter plots. Data for cers,
SMs, and S1P are expressed as pmol/mL in log scale; data for Vitamin D are in ng/mL and data for
insulin are in µU/mL; TG, TC, and LDL-C are in mg/dL; p-values from two tailed test, r value from
Pearson’s correlation.
2.4. Sphingolipid Results by LC-MS
Cers (Figure 2), SMs (Figure 3), total dihydroceramides (dhCers), total hexosylceramides (HexCer),
total dihexosylceramides (diHexCer), total monosialodihexosylganglioside (GM3), and total S1P levels
(Figure 4) were assessed between different body mass index (BMI) percentile groups. In order to
obtain a more refined characterization, Cers d18:1/16:0, d18:1/22:0, and d18:1/24:0 (Figure 2), and SMs
d18:1/18:0, d18:1/20:0, and d18:1/22:0 (Figure 3) acyl chains were also investigated.
Total Ceramides were higher in NW subjects compared to UW and OW (p-value, respectively,
<0.01 and 0.001) subjects, and in O and UW compared to OW (p-value < 0.001 and 0.05, respectively).
As expected, Cers acyl chains (d18:1/16:0, d18:1/22:0, and d18:1/24:0) followed the same trend as
total Cers.
In particular, Cer (d18:1/16:0) was higher in UW, NW, and O subjects compared to OW (p-value <
0.05 and p-value < 0.001, respectively). Cer (d18:1/22:0) showed the same pattern as Cer (d18:1/16:0) in
NW (p-value < 0.001) and O (p-value < 0.001) subjects compared to OW subjects. NW subjects also
showed higher levels of Cer (d18:1/22:0) compared to UW (p-value < 0.01). Ceramide (d18:1/24:0)
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followed the same trend as total Cers, with higher levels in NW subjects compared to UW and
OW (p-value < 0.05 and 0.001, respectively). Also, O and UW subjects showed higher levels of Cer
(d18:1/24:0) when compared to OW subjects (p-value < 0.001 and 0.05, respectively).
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Figure 2. LC-MS results for total ceramides (A), Cer (d18:1/16:0) (B), Cer (d18:1/22:0) (C), and Cer
(d18:1/24:0) (D). Data are expressed as pmol/mL in Log scale; p values are expressed as * p-value < 0.05,
** p-value < 0.01, and *** p-value < 0.001.
Conversely, total SMs (Figure 3) were higher in OW subjects compared to O (p-value < 0.01) and
NW (p-value < 0.001) subjects, and were also higher in UW compared to NW (p-value < 0.01).
SMs acyl chains followed the same trend highlighted for total SMs. In particular, SM (d18:1/18:0)
was higher in OW subjects compared to both NW (p-value < 0.001) and O (p < 0.01); this increment
was not observed in UW. SM (d18:1/20:0) was also higher in OW, comparing NW (p-value < 0.001)
and O (p-value < 0.001) groups. SM (18:1/22:0) showed the same behavior of SM (d18:1/20:0) but
significant differences were observed also in UW vs. NW, where higher levels were seen in the UW
group (p-value < 0.001) and in UW vs. OW, where UW subjects were characterized by lower levels of
SM (p-value < 0.001).
Regarding total dhCers (Figure 4), the same trend of Cers was identified—NW and O subjects
showed higher levels of serum dhCers compared to the OW group (p-value < 0.001 in both comparisons).
LC-MS analysis for total glycosphingolipids HexCer, diHexCer, and GM3 (Figure 4) identified
a characteristic pattern in all groups—NW patients have higher levels of the above-mentioned SLs
species compared to UW (p-value < 0.001). For total HexCer, NW subjects showed higher levels
also compared to OW and O (p-value < 0.05 and 0.001, respectively). For total diHexCer, O show
lower levels compared to NW (p-value < 0.001), whereas UW subjects show lower levels compared
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to OW (p-value < 0.05). Total GM3 was higher in NW compared to OW (p-value < 0.01) and to O
(p-value < 0.05) subjects. GM3 was higher in OW and O subjects compared to the UW (p-value < 0.05
in both comparisons) group.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 6 of 15 
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A clear trend for decrement was found across different BMI percentiles in S1P levels, and
statistically significant differences were observed comparing UW vs. O (p-value < 0.05) and NW vs. O
(p-value < 0.05).
To Summarize:
• Cers: UW subjects were found to have lower levels of total Cers, cer (d18:1/22:0), and cer
(d18:1/24:0) compared to NW. OW subjects showed lower levels of total Cers and all acyl Cers
chains compared to NW and O. UW and OW subjects are characterized by lower levels for total
Cers, Cer (d18:1/16:0), and Cer (d18:1/24:0).
• dhCers: Comparing UW and NW groups, lower levels of total SMs and SM (d18:1/22:0) were
observed in NW. OW subjects showed lower levels of total dhCers when compared to NW and
O groups.
• SMs: OW subjects showed higher levels of total SMs and all acyl SMs chains compared to their
NW and O counterparts. OW subjects were also characterized by higher levels of SM (d18:1/22:0)
compared to UW subjects only.
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• HexCer, diHexCer, and GM3: NW subjects showed higher levels of HexCer, dihexCer, and GM3
compared to UW and O. UW subjects had lower levels of total dihexCer compared to OW subjects
and lower levels of total GM3 compared both to OW and O groups. When comparing NW vs.
OW, total HexCer and total GM3 were higher in NW subjects.
• S1P: a decrement in S1P levels was observed in O subjects compared to both UW and NW.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 7 of 15 
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3. Discussion
This is the first study considering a sphingolipid pattern in relation to high-altitude hypoxia
exposure. In previous reports, a discrepancy between the lipid and metabolic profile of Koya children,
born and living at 3775 m a.s.l., compared with age and sex matched lowlanders [15,16], was described.
This group was characterized by slightly high glucose compared to lowlanders, lower insulin level,
lower HDL level, whereas TC/HDL-C, LDL-C/HDL-C, and triglycerides/HDL-C were higher in
high-altitude children, and particularly in overweight and obese [8,15–17,37] children. An independent
study performed in the San Pedro de Cajas district, located in the Central Andes of Peru at 4100 m a.s.l.,
showed similar results, with a high prevalence of hypertriglyceridemia (53.9%) and low HDL-C (45.3%)
in indigenous descendants of the Amerindian populations, identifying these traits as characteristic
of this population living at altitude [38]. In the present study, metabolic parameters show that mean
levels of HDL-C are lower than the safety cut-off (45 mg/dL) for UW and O subjects, while triglycerides
range from borderline (79–99 mg/dL) in UW, NW, and OW subjects to high (>110 mg/dL) in O subjects,
confirming a particular dyslipidemic pattern in this group. More importantly, results from the present
study identified the axis HDL-C, ceramide qualitative and quantitative variations, and S1P levels as
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related to hypoxia adaptation and body weight in Koya children, and indicated that total ceramide
levels correlate directly with several biochemical parameters, whereas S1P correlate indirectly.
Figure 5 summarizes the levels of sphingolipids or glycosphingolipids in the four groups and
indicates that UW and O subjects are characterized by similar glycosphingolipids levels, with S1P
values varying, being high in UW subjects and low in O subjects.
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total Cers, total dhCers, total SMs, total HexCer, total dihexCer, and total GM3. Data are expressed as
pmol/mL in Log scale; p values are expressed as * p-value < 0.05, ** p-value < 0.01, and *** p-value < 0.001.
In UW children, Cer levels seem to arise from de novo biosynthesis (being dhCers levels comparable
to NW as S1P). Conversely, O subjects are characterized by similar levels of ceramides as NW, whereas
S1P is significantly decreased, making this molecule a candidate as a central node in the metabolic
adaptation to hypoxia of Koya children.
A previous important study demonstrated that increment of S1P is associated with increased
capacity of oxygen delivery from erythrocytes, by increasing 2,3-diphosphoglycerate and activating
enzymes involved in glycolysis [39]. In the circulation, 2/3 of the S1P is bound to HDL, carried
out by the Apolipoprotein M (apoM), and 1/3 is bound to albumin [40,41]. S1P bound to apoM
promotes vasorelaxation by phosphorylating endothelial nitric oxide synthase (eNOS) [42]. The eNOS
is responsible for the generation of nitric oxide (NO) in the vascular endothelium and plays a crucial role
in vascular tone [43] and homeostasis through NO. Further, eNOS uncoupling generates endothelial
dysfunction due to superoxide anions and hydrogen peroxide overproduction. A previous study
from our group demonstrated that the NO releasing donors causes ceramide accumulation in tumor
cell lines, inducing a switching of the Akt hyperactivated signal leading to UPR (unfolded protein
response) stress response [44]. There is a possibility that ceramide accumulation is also, in this case,
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associated with UPR activation. Further studies are required to elucidate the mechanism at the basis of
ceramide levels of high-altitude living subjects.
Another study by our group on muscle tissues of Tibetans living at altitude and Tibetan
lowlanders indicates an increment of e- and nitric oxide synthase (n-NOS) in muscle tissue and
of 2,3-diphosphoglycerate (2,3-BPG). The latter is an erythrocyte-specific glycolytic intermediate, which
facilitates O2 release found to be increased in animal models overexpressing S1P [39]. In animal models,
intracellular S1P promoted increased production of 2,3-bisphosphoglycerate. In light of the present
results, the authors can postulate that UW children utilizing S1P can activate the same biochemical
pathway promoting oxygen delivery to maintain energy production and homeostasis, thereby keeping
levels of ceramides as low as possible. Conversely, O children, characterized by lower levels of S1P, are
unable to reduce ceramide levels; even if the salvage pathway is decreased, they may lose the capacity
to adapt to a lack of oxygen, therefore activating the lipogenic and lipotoxic pathways [45–48].
Another point that characterizes UW and O children is the decreased levels of glycosphingolipids
generated in the salvage pathway. The activation of Neuraminidase 3 (NEU3) sialidase in transgenic
mice expressing NEU3 sialidase caused reduced tissue and circulating levels of GM3 [49]. This molecule
was found increased in our studies on muscle tissue of animal models exposed to prolonged severe
hypoxia [50]. In the present study, it can be speculated that decreased levels of GM3, Hexosylceramides,
and dihexosylceramides can be associated with the activation of NEU 3 sialidase. The latter has been
recently described as a target of HIF 2 alpha, and thus regulated by hypoxia and associated with
obesity [51].
Concerning levels of different ceramide acyl-chains, it can be hypothesized that the elevated
C16:0-ceramide levels observed in O subjects can contribute to insulin resistance [23,52]. Ceramides
substantially upregulate fatty acid uptake and synthesis through direct or indirect mechanisms and
could be central modulators of obesity and hepatic steatosis [53]. Furthermore, specific ceramide
synthases (in this case, CerS6) have been associated with weight gain and glucose intolerance [23].
Several studies addressed the issue of the role of S1P in inflammation. In this context, O are characterized
by low levels of S1P compared to UW. It has been described that S1P improves energy homeostasis
in obesity, particularly in the early phase, acting as protective molecule to control overweight and
inflammation [54]. This observation is in agreement with our results, since in OW levels of S1P
are high compared to O. Furthermore, this molecule, in conjunction with its receptor, decreases
endothelial inflammation and promotes cardioprotection mediated by HDL-Apo-M-S1P binding and
release [55–57]. Further studies in this direction are required.
The major limitations of this study are the restricted number of subjects and the absence of a
verification study, which will require an independent group of subjects. Further data based on 2,3-BPG,
pH, partial pressure of carbon dioxide (PCO2), of oxygen (PO2), and haemoglobin-O2 saturation (SO2)
will be necessary to determine the abnormal O2 affinity or altered metabolism of RBC [58]. This data,
in conjunction with lipemia, could be supportive of our results. Another important aspect that has
not been addressed in this study for unavailability of fresh serum samples is the study of RNAs from
peripheral blood mononuclear cells (PBMCs) for the quantitative assessment of transcripts of enzymes
involved in ceramide pathways and of circulating cytokines or adipokines. Studies in this direction
are ongoing and are aimed at opening new avenues in the complex field of hypoxia tolerance in
high-altitude dwellers.
In conclusion, ceramides levels and S1P are the primary targets of hypoxia adaptation in
populations born and living at high altitude. An important point highlighted in this study is that
S1P can be a circulating biomarker of hypoxia tolerance and a valuable marker of increased risk of
metabolic syndrome and cardiac dysfunction, being directly quantifiable in blood by selected reaction
monitoring (SRM) mass spectrometry.
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4. Materials and Methods
4.1. Participants and Sample Collection
Fifty-nine children (age 5–13 years) from San Antonio de Los Cobres (3775 m a.s.l.), who were
previously enrolled [15], were classified as UW (<5th percentile), NW (5th to < 85th percentile), OW
(85th to < 95th percentile), or O (≥95th percentile) on the basis of their body mass percentiles, accordingly
to US Centers for Disease Control and Prevention (CDC) norms [59]. Children’s anthropometry—age,
gender, weight (kg) and height (cm)—are indicated in Table 1. TC (mg/dL), HDL-C (mg/dL), LDL-C
(mg/dL), Vit. D, ng/mL), fasting glucose (Glycaemia, mg/dL), fasting insulin (Insulin, µU/mL),
and triglycerides TG, mg/dL) were assessed, while BMI, TC/HDL-C ratio, and Homeostatic model
assessment of insulin resistance were calculated as follows: BMI was calculated as weight (kg) divided
by height squared (m); TC/HDL-C ratio was calculated as TC(mg/dL)/HDL-C(mg/dL); while HOMA-IR
was calculated as Glycaemia (mg/dL) × Insulin/405. Blood samples were collected after 10-h fasting.
Fasting glucose was measured by glucose oxidase, while serum lipids were assessed with Architect c
16,000 instrument (Toshiba, Kanagawa, Japan). Chemiluminiscent was utilized for the detection of
fasting insulin levels and serum Vitamin D (Abbott Laboratories, Chicago, IL, USA).
The study was carried out following the rules of the Declaration of Helsinki and was approved by
the Human Rights Committee of the Salta Health Ministry (project number: 4518; date of approval:
8 November 2010). Each caregiver and child gave written informed consent after an explanation of the
study and before its initiation.
4.2. Reagents and Chemicals
Methanol, LC-MS grade water, 3,5-Di-tert-4-butylhydroxytoluene (BHT), and ammonium formate
were from Sigma-Aldrich (Saint Louis, MO, USA). Ethanol and HPLC analytical grade chloroform
were, respectively, from J.T. Baker (Center Valley, PA, USA) and Carlo Erba (Cornaredo, MI, Italy).
Potassium hydroxide was from Merk Millipore (Burlington, MA, USA). Acetic and formic acid were
from Fluka-Analitical (Honeywell, Morris Plains, NJ, USA).
Sphinganine (d17:0), sphinganine-1-phosphate (d17:0), C12 Ceramide, Sphingomyelin (d18:1/12:0),
and Glucosyl (β) C12 Ceramide were from were from Avanti Polar Lipids (Alabaster, AL, USA).
4.3. Lipid Extraction
Sphingolipids were extracted from sera according to a previous study [60], with minor modification.
Briefly, 0.1 mL of serum was mixed with 0.1 mL of ultrapure water and 1.5 mL of Methanol/chloroform
2:1, and fortified with internal standards 200 pmol: Sphinganine (d17:0), sphinganine-1-phosphate
(d17:0), C12 Ceramide (d18:1/12:0), C12 Sphingomyelin (d18:1/12:0), and Glucosyl (β) C12 Ceramide.
Samples were briefly sonicated and heated at 48 ◦C overnight. Then, 0.15 mL of KOH 1 M in methanol
was added to every sample, and after 2-h incubation at 37 ◦C, the solution was neutralized with 0.15 mL
of acetic acid 1 M and dried with Speedvac. Samples were then resuspended in 0.5 mL of methanol
and transferred to a clean Eppendorf tube. Samples were dried, resuspended in 0.15 mL of methanol,
and centrifuged for 3 min at 10,000× g. Liquid phases were collected in UPLC glass vials and stored at
−80 ◦C.
4.4. UPLC-MS for Sphingolipids
Liquid chromatography-mass spectrometer configuration included a Waters Acquity UPLC system
linked to a Waters LCT Premier Orthogonal Accelerated Time of Flight Mass Spectrometer (Waters,
Millford, MA, USA). The instrument operated in positive or negative electrospray ionization mode.
Full scans were obtained in a window, ranging from 50 to 1500 Da. Accuracy and reproducibility were
maintained employing an independent reference spray via LockSpray. First, 10 µL of sphingolipid
extract were injected and separated on an analytical column, kept at 30 ◦C, 100 mm × 2.1 mm id,
1.7 µm C8 Acquity UPLC BEH (Waters), using the following linear gradient: 0.0 min: 80% B; 3 min:
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90% B; 6 min: 90% B; 15 min: 99% B; 18 min: 99% B; 20 min: 80% B, at 0.3 mL/min flow rate. Phase B
consisted of 1 mM ammonium formate in methanol, 0.05 mM formic acid, while phase A was 2 mM
ammonium formate in H2O, with 0.05 mM formic acid. Sphingolipids quantification was carried out
using the ion chromatogram obtained for each compound using 50 mDa windows. The linear dynamic
range was determined by injection of standard mixtures. Positive identification of compounds was
based on the accurate mass measurement, with an error <5 ppm and its retention time, compared to
that of a standard (± 2%). Mass spectra were analyzed by MassLynx™ 4.1 Software (Waters, Millford,
MA, USA), and lipids were annotated as lipid subclasses as follows (sphingosine backbone/number of
carbon atoms of the fatty acid: number of unsaturations of the fatty acid).
4.5. MRM Analysis for S1P
S1P was quantified using a Xevo TQ-MS mass spectrometer (Waters, Millford, MA, USA), where
10 µl of sphingolipid extract were injected and separated on an analytical column, kept at 30 ◦C,
100 mm × 2.1 mm id, 1.7 µm C8 Acquity UPLC BEH (Waters), with the following gradient: 0.0 min:
80% B; 3 min: 90% B; 6 min: 90% B; 9 min: 99% B; 12 min: 99% B; 14 min: 80% B, at 0.3 mL/min
flow rate. Phase A and phase B were the same as above. An electrospray interface operating in
positive ion mode was employed to obtain MS/MS spectra by acquiring MRM transitions of: C17
sphinganine-1-phosphate, 368.4–252.4, collision energy 18 eV; and S1P, 380.4–264.4 Da, collision energy
16 eV. Mass spectra were analyzed by MassLynx™ 4.1 Software.
4.6. Statistical Analysis
Participants were grouped according to their BMI percentiles and their characteristics were
described using median and interquartile range (if continuous) or counts and percentages (if categorical).
Comparison of age, weight, height, BMI, TC, HDL-C, CT/HDL, LDL-C, Vitamin D, glycaemia,
HOMA-IR, insulin, and TG were investigated between groups using One way ANOVA with Bonferroni’s
correction if data were normally distributed, otherwise the Kruskal-Wallis’ with Dunn’s correction
was adopted. Correlation tables for sphingolipids and biochemical parameters were obtained using
Pearson’s or Spearman’s correlation, when data were parametrically or not distributed, respectively.
Differences in Cers, dhCers, SMs, dhSMs, HexCers, diHexCers, GM3, and S1P from LC-MS and
LC-MS/MS quantitative data were assessed among groups.
Statistical analyses were performed using SigmaPlot software version 12.0 and Prism software
version 7.0.
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Abbreviations
UW Underweight
NW Normal weight
OW Overweight
O Obese
LC-MS/MS Liquid Chromatography Mass Spectrometry/Mass spectrometry
Cers Ceramides
S1P Sphingosine 1 phosphate
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SMs Sphingomyelins
HDL-C High density lipoprotein-cholesterol
LDL-C Low density lipoprotein-cholesterol
A.s.l Above sea level
HIF Hypoxia inducible factor
EPAS1 Endothelial PAS Domain Protein 1
EGLN1 Egl-9 Family Hypoxia Inducible Factor 1
NOS2A Nitric oxide synthase 2
CH Chicoana
SAC San Antonio de los Cobres
BA Buenos Aires
CerS Ceramide Synthases
SphK Sphingosine Kinase
ER Endoplasmic reticulum
HOMA-IR Homeostatic model assessment of insulin resistance
TC Total Cholesterol
TG Triglycerides
Vit. D Vitamin D
dhCers Dihydroceramides
HexCer Hexosylceramides
DiHexCer DiHexosylceramides
GM3 Monosialodihexosylganglioside
BMI Body Mass Index
apoM Apolipoprotein M
eNOS Endothelial nitric oxide synthase
NO Nitric oxide
UPR Unfolded protein response
2,3-BPG 2,3-diphosphoglycerate
NEU3 Neuraminidase 3
PCO2 Partial pressure of carbon dioxide
PO2 Partial pressure of oxygen
SO2 Haemoglobin-O2 saturation
n-NOS Nitric oxide synthase
PBMCs Peripheral blood mononuclear cells
SRM Selected Reaction Monitoring
CDC Centers for Disease Control and Prevention
BHT 3,5-Di-tert-4-butylhydroxytoluene
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